It has recently been reported that surgical treatment after reevaluation at the end of chemotherapy and/or radiotherapy improves the prognosis of patients with non-small cell lung cancer (NSCLC), who were initially found to be unresectable or non-operable (especially due to N 2 disease). [1, 2] In this group, there are no certain criteria regarding the selection of these patients for surgery. However, the generally accepted opinion is that patients who have no findings of N 2 disease and who undergo complete resection benefit the most. [3] [4] [5] [6] [7] [8] [9] Various studies have demonstrated that a pathologically complete or near complete response is also one of the important prognostic factors. [10] [11] [12] [13] [14] There is no certainty about the evaluation of complete response after treatment. When compared with other conventional methods, positron emission tomography/ computed tomography (PET/CT), which is more likely to produce metabolic information than anatomical information, has been considered to be the most appropriate imaging method; however, its efficacy is limited due to the inadequacy of detecting the small amount of living tumor cells. [15] [16] [17] In patients who were unresectable or non-operable in the initial evaluation with complete or nearly complete response after chemotherapy and/or radiotherapy, surgical treatment may be performed to particularly avoid local recurrence unless living tumor cells were present.
Therefore, in this study, we aimed to evaluate survival and recurrence rates in pT 0 /T 1 N 0 /M 0 non-small cell lung cancer patients who were performed surgical resection after chemotherapy and/or radiotherapy, and investigate the role of PET/CT in preoperative evaluation.
PATIENTS AND METHODS
Between November 2001 and November 2010, lung resection (lobectomy or pneumonectomy) was performed on 195 patients with NSCLC after at least two cycles of chemotherapy and/or 4500 cGy radiotherapy. Operative mortality was observed in 10 patients. From the remaining 185 patients, 53 had nodal metastasis and 78 were pT 2 , pT 3 , and pT 4 . The remaining 54 patients (52 males, 2 females; mean age 59.2±9.3 years; range 42 to 77 years) without lymph node metastasis, with no living tumor cells (T 0 ) or with tumors found in an area less than 3 cm with no invasion to the surrounding structures (T 1 ) postoperatively were included in this retrospective study.
Patients were initially evaluated with thoracic CT, bronchoscopy, respiratory function tests (RFT), and 18 patients with PET/CT, additionally. Those considered to be unresectable were clinically staged according to radiological findings. Invasive staging methods including transbronchial needle aspiration biopsy, mediastinoscopy, and video-assisted thoracoscopic surgery were performed for histological confirmation in those with resectable disease and N 2 findings.
At least two cycles of platin-based chemotherapy or 4500 cGy radiotherapy were used in patients with N 2 disease. Patients were reevaluated after treatment with thoracic CT, bronchoscopy, RFT, and PET/CT. Patients who were resectable without any signs of N 2 disease underwent surgery if they had sufficient cardiopulmonary reserves. Patients who were suspected to have N 2 disease were assessed with invasive staging methods and resection was performed on patients without N 2 .
Patients with a history of previous distant metastasis and operative mortality were excluded even if they met the inclusion criteria. Deaths in the postoperative first 30 days or postoperative mortality before the patient was discharged were accepted as operative mortality.
Pathologically complete response (pT 0 ) was described as no viable cancer cells determined in the histopathological analysis of all resected materials. Patients with a tumor size less than 3 cm and irrelevant to any surrounding structure were defined as pT 1 . Patients were analyzed according to recurrence and survival properties and compared as to whether they had T 0 or T 1 .
Moreover, patients who were performed PET/CT in the period between surgery and chemotherapy and/or radiotherapy were analyzed and assessed by a nuclear medicine specialist visually (positive or negative). The accordance between pathology and PET/CT was analyzed.
All patients were scanned with PET/CT (Biograph LSO Duo, Siemens Medical Solutions, Inc. Malvern, PA) for staging before treatment. Patients with fasting glycaemia level of less than 200 mg/dL were accepted. Patients were scanned 60 minutes after intravenous injection of 370-555 MBq fluorodeoxyglucose (FDG). At first, scanned and tomographic section views were achieved with a two-section tomography between the vertex and upper thigh (50 mAs "Care Dose", 110 kV). The three-dimensional mode scan was performed for three minutes to achieve a PET view between seven to nine mattresses according to the height of the patient.
In the processing unit, the fusion sections were obtained in the axial, sagittal, and coronal planes after PET views, in which the correction of attenuation was completed with CT data. The obtained data were visually analyzed by two nuclear medicine clinicians separately, and evaluated with semi-quantitative data. Lesions with higher FDG uptake than mediastinal basal activity level were considered pathologic.
The study was approved by the Suat Seren Institutional Review Board Ethics Committee of the Chest Diseases and Thoracic Surgery Training and Research Hospital. Written informed consent was obtained from each patient, and the study was conducted in accordance with the principles of the Declaration of Helsinki.
Statistical analysis
SPSS version 9.0 (SPSS Inc. Chicago, IL, USA) package program was used for statistical analysis. Fisher's exact test or Pearson's chi-square tests were used to compare the variables. In the survival analysis, the time interval between the day of surgery to last control or death was taken into account. Survival rates were evaluated with the Kaplan-Meier method and were compared with log-rank method. The forward stepwise method was used in the logistic regression analysis. P values greater than 0.5 were accepted as statistically significant. 
RESULTS
Overall survival rates according to clinical and tumor characteristics of the patients are listed in Table 1 . The mean follow-up time was 37.3±26.5 months (range 2.5 to 103.7 months) and the five-year general survival rate was 68.7% ( Figure 1 ).
The five-year survival rate was 53% in the pT 1 group and 86.3% in the pT 0 group, and the difference was not statistically significant (p= 0.1) (Figure 2 ). There was also no significant difference between two groups in terms of the variables affecting survival, except for preoperative chemotherapy.
Recurrence rates in the pT 0 group were significantly lower than those in the pT 1 group (4.0% and 27.6%, respectively; p= 0.03) ( (Table 3) . Sensitivity, specificity, positive and negative predictive value of preoperative PET/CT were 78%, 56%, 64%, and 71%, respectively (Table 4) .
DISCUSSION
Treatment for locally advanced (stage 3A and IIIB) NSCLC continues to be controversial. With these patients, surgical treatment alone is far from providing the expected results, and multimodality treatments (surgical treatment with chemotherapy and/or radiotherapy) are shown to increase resectability and survival rates. In particular, patients who had regression in N 2 disease and underwent complete resection are reported to have better prognosis. [3] [4] [5] [6] [7] [8] [9] The issue is to be able to clearly detect the nodal status preoperatively and the degree of the response to the neoadjuvant treatment regimen. It is mandatory to perform PET/CT and evaluate the results and obtain samples from the nodal involvement areas using invasive methods. Surgical exploration aiming R 0 resection should be performed in cases where the response to treatment is evaluated as sterilization/ medical clearance beyond regression.
Patients that received chemotherapy and/or radiotherapy were reported to have complete response at rates of 4% to 23%, respectively. Near complete response was detected in approximately 10% of cases. Patients that received high dose radiotherapy in addition to chemotherapy are reported to have complete pathological response rates up to 55%. [5] [6] [7] [8] [9] [18] [19] [20] [21] [22] [23] [24] [25] [26] Pathologically complete or near complete response is reported to be a prognostic factor by some authors. [10] [11] [12] [13] [14] Although prognosis is preferably good in this group of patients, distant recurrences in particular may reduce success rates. [3, 8, 25] However, in cases when local control cannot be achieved completely, the survival expectancy of R 0 resections or R 1 -R 2 resections to diminish the tumor burden relying on the adjuvant treatment regimens may not be met. Data obtained by PET/CT may be depreciated because of the high negative prognostic value of the method, especially in small tumoral masses. Because of the challenges and relatively low applicability of re-mediastinoscopy, one should be careful when comparing the values before and after the neoadjuvant therapy and one may select to perform the mediastinoscopic examination after the treatment, when necessary. Video-assisted thoracoscopic surgery should always be included in the staging and the number of exploratory thoracotomies should be decreased. Another important issue is the dimensions of the resection. The planned dimensions in the pre-treatment period may be diminished after the treatment. Extensive resections do not always mean complete resections. However, mortality and morbidity issues may directly affect survival. Therefore, if it is possible to obtain R 0 resections after treatment with more limited resections, the decisions of extensive resections made before the treatment may be revised.
Kim et al. [21] reported five-year survival rates in pneumonectomy patients after chemoradiotherapy; 48% of those had a pathologically complete response and 43% were at stage 1. Decaluwé et al. [11] demonstrated that patients with pT 0-1 tumors who underwent lung resection after chemotherapy because of resectable N 2 diseases had significantly better survival rates than pT 2-4 patients (survival rates 64.9% and 24.3%, respectively; p<0.01). Five-year survival rates in pT 0 and pT 1 patients were 83.6% and 53.7%, respectively, which were similar to the survival rates reported for pT 1 and pT 2 tumors operated on without any preoperative treatment. [27] [28] [29] [30] [31] In particular, distant recurrences are a serious problem in the postoperative period in patients with complete or near complete response after oncological treatments. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In the current study, recurrence developed in one patient in the pT 0 tumor group, which was a distant recurrence. Four of the eight recurrences in the pT 1 tumor group were distant and one was both local and distant. In the multivariate analysis, the only variable that had an effect on recurrence was the pathological existence of the tumor.
Currently, while assessing the response after chemotherapy and/or radiotherapy, serial measurements of tumor diameter are achieved with CT. However, due to the changes in living tumor fractions, tumor tissue shifting with necrotic and fibrotic tissue or accompanying atelectasia might not result in major changes in tumor size. As a result, these conventional imaging methods may not always display the difference between those various kinds of tissue types.
Positron emission tomography is more useful than conventional methods to obtain information about metabolic response after neoadjuvant chemotherapy by comparing the FDG uptakes before and after the treatment. [32, 33] However, due to its limited resolution in detecting a limited number of living tumor cells and relatively low metabolic signal of small tumors, the efficacy of PET decreases. [15] [16] [17] In addition, its success in defining complete or near complete response is more limited in patients who received oncological treatment before surgery compared to those who did not. [34] Cerfolio et al. [35] reported the positive predictive value of PET as 100% and negative predictive value as 67% (one out of three patients was a false negative) after chemotherapy. In the current study, the accuracy rates of PET/CT in patients with pT 0 and pT 1 tumors were 56% and 78%, respectively.
In conclusion, surgical treatment was applied to prevent local recurrence and due to the lack of proving the presence of living tumor cells in patients who were accepted as unresectable or nonoperable in the beginning and who had complete or near complete response after chemotherapy and/or radiotherapy. For those patients, different applications may be administered in the postoperative period. Usually, close follow-up may be conducted without any additional therapy; while at other times, adjuvant therapy may be performed. In addition, distant metastasis is another problem appearing in these patients and it is not clear if postoperative prophylactic therapy, as in small cell lung cancer, is necessary or not. Survival rates of pT 0 and pT 1 non-small cell lung cancer patients who underwent lung resection surgery after chemotherapy and/or radiotherapy with any lymph node metastasis are similar with those who had surgery without induction therapy. The accuracy of positron emission tomography/computed tomography in determining the existence of viable tumor cells was lower than expected.
